Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide

Cancer Immunology Immunotherapy(2020)10.1007/s00262-019-02477-8Source: DataRank Database

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide is a research paper published in Cancer Immunology Immunotherapy (2020). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.49)OA: greenTopics (60)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Sachin Kumar Singh Chauhan ORCID,J.M. Daly ORCID,Alessandro Natoni ORCID,Heather Fairfield ORCID,Robert B. Henderson ORCID

Live enrichment

PubMed:31919623 OpenAlex:https://openalex.org/W3000621340

ONK Therapeutics

Grant: ONK Therapeutics

National Institutes of Health

Grant: P20GM121301

American Cancer Society

Grant: RSG-19-037-01-LIB

National Institutes of Health

Grant: 3P20GM121301-05S1

COBRE in Mesenchymal and Neural Regulation of Metabolic Networks - Metabolic Phenotyping Equipment

NIGMS NIH HHS

Grant: U54 GM115516

FWCI

1.49

Citation Percentile

0.8%

Citation Trend

2020

2021

2022

2023

2024

greenLicense: Springer TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7133790

publisherhttp://link.springer.com/content/pdf/10.1007/s00262-019-02477-8.pdf

publisherhttp://link.springer.com/article/10.1007/s00262-019-02477-8/fulltext.html

journalhttps://doi.org/10.1007/s00262-019-02477-8

Fields of Study

Multiple Myeloma Research and TreatmentsImmune Cell Function and InteractionPeptidase Inhibition and Analysis03 medical and health sciences0302 clinical medicineADP-ribosyl Cyclase 1AnimalsAntibodies, MonoclonalCell Line, TumorHumansKiller Cells, NaturalMiceMultiple MyelomaReceptors, IgG

MeSH Terms

AnimalsAntibodies, MonoclonalHumansKiller Cells, NaturalMultiple MyelomaReceptors, IgGCell Line, TumorMiceADP-ribosyl Cyclase 1

Keywords

DaratumumabAntibody-dependent cell-mediated cytotoxicityNK-92ImmunologyCD16Lymphokine-activated killer cellCancer researchCytotoxic T cellNatural killer cellBiologyInterleukin 21Ex vivoCD38PopulationMonoclonal antibodyAntibodyMedicineImmune systemIn vivoT cellCD8CD34Cell biologyStem cellIn vitroKiller Cells, NaturalMiceCell Line, TumorReceptors, IgGADCC; Daratumumab; Multiple myeloma; NK cellsAnimalsAntibodies, MonoclonalHumansMultiple MyelomaADP-ribosyl Cyclase 1ADCCNK cells

Sustainable Development Goals

SDG 0: Good health and well-being